Back to Search
TAWANDA GUMBO, M.D.
M.D.
Infectious Disease Physician
NPI: 1255323317Individual
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
002080(NY)41626(TX)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
PMID 19451303·Antimicrob Agents Chemother·2009
8-other
Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy.
PMID 18175265·Curr Opin Drug Discov Devel·2008
6-review
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
PMID 17975408·Curr Opin Infect Dis·2007
6-review
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
PMID 17724157·Antimicrob Agents Chemother·2007
8-other
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
PMID 17438043·Antimicrob Agents Chemother·2007
8-other
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
PMID 17194830·Antimicrob Agents Chemother·2007
7-preclinical
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
PMID 16954319·Antimicrob Agents Chemother·2006
7-preclinical
Anidulafungin in the treatment of invasive fungal infections.
PMID 18728722·Ther Clin Risk Manag·2008
8-other
Population pharmacokinetics of micafungin in adult patients.
PMID 18024052·Diagn Microbiol Infect Dis·2008
8-other
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
PMID 17638696·Antimicrob Agents Chemother·2007
8-other
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
PMID 17191164·J Infect Dis·2007
8-other
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
PMID 17143821·Clin Infect Dis·2007
7-preclinical
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
PMID 16421797·Clin Infect Dis·2006
6-review
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
PMID 16304173·Antimicrob Agents Chemother·2005
7-preclinical
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
PMID 16048921·Antimicrob Agents Chemother·2005
8-other
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
PMID 15478070·J Infect Dis·2004
8-other
Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon.
PMID 12578150·Scand J Infect Dis·2002
8-other
Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome.
PMID 11791100·Pediatr Infect Dis J·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- UT SOUTHWESTERN MEDICAL CTR, 5323 HARRY HINES BLVD
DALLAS, TX 75390 - Phone
- (214) 648-9914
Quick Facts
- NPI
- 1255323317
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile